Stories

The rare disease community continues to strive for innovative solutions to meet patient needs and ensure no person living with a rare disease is left behind.  

As part of our commitment to accelerating transformative research and development, we’re excited to announce that our Golden Ticket Competition is now open! Through our continued partnership with Biolabs, we’re delighted to be offering the brightest mi

This year marks the 17th anniversary since the discovery of the ACVR1 gene was announced, a major scientific milestone in fibrodysplasia ossificans progressiva (FOP) research that helped us understand what causes the condition. On April 23,

Learn how to engage with our campaign and help protect your liver health. Every year, Liver Cancer Awareness Month (LCAM) is an opportunity to bring the sixth most prevalent cancer globally to the forefront of conversation, promoting awareness and the impo

Hear what Ipsen CEO David Loew has to say about our strong full year and Q4 2022 results.

Ipsen leaders will attend the J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco, California. This event will bring together biotech companies, clinical researchers, investors and analysts from all over the world to learn about hea

‘Invisible’ diseases like primary biliary cholangitis (PBC) can be difficult to recognise, diagnose and to manage effectively. Here Prof. Gideon Hirschfield (University of Toronto, Departments of Medicine, Immunology and Medical Sciences) and Robert Mi

You can never truly understand what it’s like to live with an ultra-rare condition unless you’ve experienced it for yourself. And with this in mind, we recently embarked on a project to help healthcare professionals experience what it’s like to live

In December 2021, Ipsen received ISO 37001 certification for its anti-corruption management systems by Eurocompliance, a certification organization dedicated to the prevention of corruption. 

“Our growth platforms have delivered strong sales performance, reflecting improving commercial execution and the strength for our portfolio.” CEO David Loew